These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 14982308

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 23. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
    Panayi GS, Hainsworth JD, Looney RJ, Keystone EC.
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Rituximab in diffuse large B-cell lymphoma.
    Coiffier B.
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
    [No Abstract] [Full Text] [Related]

  • 27. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
    Williams ME.
    Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
    [No Abstract] [Full Text] [Related]

  • 28. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K, Terui Y.
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [Abstract] [Full Text] [Related]

  • 29. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E.
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
    Ozgönenel B, Moonka D, Savaşan S.
    Am J Hematol; 2006 Apr; 81(4):302. PubMed ID: 16550511
    [No Abstract] [Full Text] [Related]

  • 32. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP.
    Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
    [Abstract] [Full Text] [Related]

  • 33. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [Abstract] [Full Text] [Related]

  • 34. Non-Hodgkin's lymphoma presenting as multiple bone lesions and hypercalcemia.
    Takasaki H, Kanamori H, Takabayashi M, Yamaji S, Koharazawa H, Taguchi J, Fujimaki K, Ishigatsubo Y.
    Am J Hematol; 2006 Jun 15; 81(6):439-42. PubMed ID: 16680736
    [Abstract] [Full Text] [Related]

  • 35. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
    Sirvent-Von Bueltzingsloewen A, Sirvent N, Morand P, Cassuto JP.
    Med Pediatr Oncol; 2003 Jun 15; 40(6):408-9. PubMed ID: 12692818
    [No Abstract] [Full Text] [Related]

  • 36. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C, Castillo J.
    Curr Opin Mol Ther; 2009 Apr 15; 11(2):200-7. PubMed ID: 19330725
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.
    Clin Cancer Res; 2004 Dec 01; 10(23):7842-51. PubMed ID: 15585616
    [Abstract] [Full Text] [Related]

  • 39. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K.
    Clin Cancer Res; 2009 May 15; 15(10):3624-32. PubMed ID: 19417028
    [Abstract] [Full Text] [Related]

  • 40. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.